Recent trial results indicate that Semaglutide, known commercially as Ozempic, could slow the progression of kidney disease in people with type 2 diabetes. This condition, which arises from the body’s resistance to insulin, significantly increases the risk of chronic kidney disease. Used alongside diet and exercise, Ozempic has shown promising results in improving blood sugar control in diabetic patients.
The latest trial data revealed a 29% reduction in Alzheimer’s progression over 18 months, compared to a placebo, echoing similar results seen with Leqembi, another Alzheimer’s drug. The FDA’s expected decision on Ozempic’s approval has been postponed as the agency seeks further input from its independent advisory committee on concerns regarding the drug’s safety and efficacy.
If approved, Ozempic would be among a new class of Alzheimer’s drugs in the U.S., including Leqembi and Biogen’s Aduhelm, designed to target amyloid in the brain, a key Alzheimer’s marker. However, concerns over serious side effects, including brain swelling and bleeding, have been raised.
These drugs, particularly Biogen’s Aduhelm, have been contentious. Aduhelm received accelerated FDA approval in 2021 despite advisory committee reservations, leading to an 18-month congressional investigation that criticized the FDA’s approval process.
The high initial cost of Aduhelm also sparked controversy, ultimately leading to its withdrawal from the market. With Ozempic potentially joining this controversial drug class, the ongoing debate highlights the complex balance between advancing medical treatments and ensuring patient safety and affordability.